Platelets and autoimmunity

European Journal of Clinical Investigation

Volumn 43, Issue 7, 2013, Pages 746-757

  Habets, Kim L L ^a   Huizinga, Tom W J ^a   Toes, René E M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Autoimmune diseases; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CCL1 CHEMOKINE; CD40 LIGAND; CHEMOKINE RECEPTOR CXCR4; COLLAGEN; COLLAGEN RECEPTOR; CXCL1 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FIBRINOGEN; FIBRONECTIN; GLYCOPROTEIN IB ALPHA; GRANULOCYTE CHEMOTACTIC PROTEIN 2; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN E RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; RANTES; RECEPTOR; SEROTONIN; THROMBIN; THROMBOXANE A2; THYMUS AND ACTIVATION REGULATED CHEMOKINE; VIMENTIN; VON WILLEBRAND FACTOR;

ARTICLE; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ADHESION; CELL SURFACE; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; COMPLEMENT INHIBITION; FIBRIN DEPOSITION; HEART INFARCTION; HUMAN; LEUKOCYTE; MULTIPLE SCLEROSIS; NEUTROPHIL; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPOIESIS;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; BLOOD PLATELETS; HUMANS; INFLAMMATION; PLATELET ACTIVATION; THROMBOSIS;

EID: 84878901062     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12101     Document Type: Article

References (122)

1. Hartwig J, Italiano J Jr. The birth of the platelet. J Thromb Haemost 2003;1:1580-6.
2. Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol 2011;11:264-74.
3. Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost 2011;105(Suppl 1):S13-33.
4. Langer HF, Choi EY, Zhou H, Schleicher R, Chung KJ, Tang Z et al. Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ Res 2012;110:1202-10.
5. Lievens D, von Hundelshausen P. Platelets in atherosclerosis. Thromb Haemost 2011;106:827-38.
6. Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, Weinblatt ME et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 2010;327:580-3.
7. Grammer AC, Lipsky PE. CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. Arthritis Rheum 2002;46:1417-29.
8. Ramirez GA, Franchini S, Rovere-Querini P, Sabbadini MG, Manfredi AA, Maugeri N et al. The role of platelets in the pathogenesis of systemic sclerosis. Front Immunol 2012;3:160.
9. Senzel L, Gnatenko DV, Bahou WF. The platelet proteome. Curr Opin Hematol 2009;16:329-33.
10. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008;359:938-49.
11. Cerletti C, Tamburrelli C, Izzi B, Gianfagna F, de Gaetano G. Platelet-leukocyte interactions in thrombosis. Thromb Res 2012;129:263-6.
12. Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development. Blood 2003;101:2661-6.
13. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003;9:61-7.
14. Schmitt-Sody M, Metz P, Gottschalk O, Birkenmaier C, Zysk S, Veihelmann A et al. Platelet P-selectin is significantly involved in leukocyte-endothelial cell interaction in murine antigen-induced arthritis. Platelets 2007;18:365-72.
15. Bhatia GS, Sosin MD, Patel JV, Grindulis KA, Khattak FH, Davis RC et al. Plasma indices of endothelial and platelet activation in rheumatoid disease: relationship to cardiovascular co-morbidity. Int J Cardiol 2009;134:97-103.
16. Cheng T, Li FF, Zhao S, Peng XC, Zhang XL. Soluble P selectin in synovial fluid level is correlated with the radiographic severity of knee osteoarthritis. Clin Chim Acta 2010;411:1529-31.
17. Ertenli I, Kiraz S, Arici M, Haznedaroglu IC, Calguneri M, Celik I et al. P-selectin as a circulating molecular marker in rheumatoid arthritis with thrombocytosis. J Rheumatol 1998;25:1054-8.
18. Kisucka J, Chauhan AK, Zhao BQ, Patten IS, Yesilaltay A, Krieger M et al. Elevated levels of soluble P-selectin in mice alter blood-brain barrier function, exacerbate stroke, and promote atherosclerosis. Blood 2009;113:6015-22.
19. Sfikakis PP, Charalambopoulos D, Vaiopoulos G, Mavrikakis M. Circulating P- and L-selectin and T-lymphocyte activation and patients with autoimmune rheumatic diseases. Clin Rheumatol 1999;18:28-32.
20. Gawaz M, Brand K, Dickfeld T, Pogatsa-Murray G, Page S, Bogner C et al. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. Atherosclerosis 2000;148:75-85.
21. Kaplanski G, Farnarier C, Kaplanski S, Porat R, Shapiro L, Bongrand P et al. Interleukin-1 induces interleukin-8 secretion from endothelial cells by a juxtacrine mechanism. Blood 1994;84:4242-8.
22. Langer HF, Gawaz M. Platelet-vessel wall interactions in atherosclerotic disease. Thromb Haemost 2008;99:480-6.
23. Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 1996;14:591-617.
24. Lievens D, Eijgelaar WJ, Biessen EA, Daemen MJ, Lutgens E. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb Haemost 2009;102:206-14.
25. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-4.
26. Elzey BD, Ratliff TL, Sowa JM, Crist SA. Platelet CD40L at the interface of adaptive immunity. Thromb Res 2011;127:180-3.
27. Kissel K, Berber S, Nockher A, Santoso S, Bein G, Hackstein H Human platelets target dendritic cell differentiation and production of proinflammatory cytokines. Transfusion 2006;46:818-27.
28. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003;348:1104-11.
29. Prahalad S, Martins TB, Tebo AE, Whiting A, Clifford B, Zeft AS et al. Elevated serum levels of soluble CD154 in children with juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2008;6:8.
30. Tamura N, Kobayashi S, Kato K, Bando H, Haruta K, Oyanagi M et al. Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. J Rheumatol 2001;28:2583-90.
31. Projahn D, Koenen RR. Platelets: key players in vascular inflammation. J Leukoc Biol 2012;92:1167-75.
32. Flad HD, Brandt E. Platelet-derived chemokines: pathophysiology and therapeutic aspects. Cell Mol Life Sci 2010;67:2363-86.
33. von Hundelshausen P, Koenen RR, Sack M, Mause SF, Adriaens W, Proudfoot AE et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 2005;105:924-30.
34. Koenen RR, von Hundelshausen P, Nesmelova IV, Zernecke A, Liehn EA, Sarabi A et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med 2009;15:97-103.
35. Endresen GK. Evidence for activation of platelets in the synovial fluid from patients with rheumatoid arthritis. Rheumatol Int 1989;9:19-24.
36. Erdem H, Pay S, Musabak U, Simsek I, Dinc A, Pekel A et al. Synovial angiostatic non-ELR CXC chemokines in inflammatory arthritides: does CXCL4 designate chronicity of synovitis? Rheumatol Int 2007;27:969-73.
37. Trocme C, Marotte H, Baillet A, Pallot-Prades B, Garin J, Grange L et al. Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis 2009;68:1328-33.
38. Massberg S, Konrad I, Schurzinger K, Lorenz M, Schneider S, Zohlnhoefer D et al. Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J Exp Med 2006;203:1221-33.
39. Stellos K, Langer H, Daub K, Schoenberger T, Gauss A, Geisler T et al. Platelet-derived stromal cell-derived factor-1 regulates adhesion and promotes differentiation of human CD34+ cells to endothelial progenitor cells. Circulation 2008;117:206-15.
40. Hristov M, Zernecke A, Bidzhekov K, Liehn EA, Shagdarsuren E, Ludwig E et al. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res 2007;100:590-7.
41. von Hundelshausen P, Petersen F, Brandt E. Platelet-derived chemokines in vascular biology. Thromb Haemost 2007;97:704-13.
42. Durk T, Panther E, Muller T, Sorichter S, Ferrari D, Pizzirani C et al. 5-Hydroxytryptamine modulates cytokine and chemokine production in LPS-primed human monocytes via stimulation of different 5-HTR subtypes. Int Immunol 2005;17:599-606.
43. Leon-Ponte M, Ahern GP, O'Connell PJ. Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. Blood 2007;109:3139-46.
44. Soga F, Katoh N, Inoue T, Kishimoto S. Serotonin activates human monocytes and prevents apoptosis. J Invest Dermatol 2007;127:1947-55.
45. Duerschmied D, Suidan GL, Demers M, Herr N, Carbo C, Brill A et al. Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood 2012;121:1008-15.
46. Cloutier N, Pare A, Farndale RW, Schumacher HR, Nigrovic PA, Lacroix S et al. Platelets can enhance vascular permeability. Blood 2012;120:1334-43.
47. Hamad OA, Nilsson PH, Wouters D, Lambris JD, Ekdahl KN, Nilsson B. Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1. J Immunol 2010;184:2686-92.
48. del Conde I, Nabi F, Tonda R, Thiagarajan P, Lopez JA, Kleiman NS et al. Effect of P-selectin on phosphatidylserine exposure and surface-dependent thrombin generation on monocytes. Arterioscler Thromb Vasc Biol 2005;25:1065-70.
49. Hamad OA, Ekdahl KN, Nilsson PH, Andersson J, Magotti P, Lambris JD et al. Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. J Thromb Haemost 2008;6:1413-21.
50. Peerschke EI, Yin W, Grigg SE, Ghebrehiwet B. Blood platelets activate the classical pathway of human complement. J Thromb Haemost 2006;4:2035-42.
51. Okayama M, Oguri K, Fujiwara Y, Nakanishi H, Yonekura H, Kondo T et al. Purification and characterization of human platelet proteoglycan. Biochem J 1986;233:73-81.
52. Donato JL, Nogueira MD, Marcondes S, Antunes E, Nader HB, Dietrich CP et al. The kinetics of chondroitin 4-sulfate release from stimulated platelets and its relation to thromboxane A2 formation and granule secretion. Braz J Med Biol Res 1994;27:2163-7.
53. Peerschke EI, Yin W, Ghebrehiwet B. Platelet mediated complement activation. Adv Exp Med Biol 2008;632:81-91.
54. Yin W, Ghebrehiwet B, Peerschke EI. Expression of complement components and inhibitors on platelet microparticles. Platelets 2008;19:225-33.
55. King M, McDermott P, Schreiber AD. Characterization of the Fc gamma receptor on human platelets. Cell Immunol 1990;128:462-79.
56. Huang ZY, Chien P, Indik ZK, Schreiber AD. Human platelet FcgammaRIIA and phagocytes in immune-complex clearance. Mol Immunol 2011;48:691-6.
57. Tsuji M, Ezumi Y, Arai M, Takayama H. A novel association of Fc receptor gamma-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. J Biol Chem 1997;272:23528-31.
58. Moroi M, Jung SM. Platelet glycoprotein VI: its structure and function. Thromb Res 2004;114:221-33.
59. Capron M, Jouault T, Prin L, Joseph M, Ameisen JC, Butterworth E et al. Functional study of a monoclonal antibody to IgE Fc receptor (Fc epsilon R2) of eosinophils, platelets, and macrophages. J Exp Med 1986;164:72-89.
60. Joseph M, Gounni AS, Kusnierz JP, Vorng H, Sarfati M, Kinet JP et al. Expression and functions of the high-affinity IgE receptor on human platelets and megakaryocyte precursors. Eur J Immunol 1997;27:2212-8.
61. Kasperska-Zajac A, Rogala B. Platelet activation during allergic inflammation. Inflammation 2007;30:161-6.
62. Tamagawa-Mineoka R, Katoh N, Kishimoto S. Platelets play important roles in the late phase of the immediate hypersensitivity reaction. J Allergy Clin Immunol 2009;123:581-7, 587. e581-589.
63. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004;50:709-15.
64. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:797-808.
65. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005;7:R949-58.
66. Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA, Ioan-Facsinay A, Drijfhout JW, van Tol MJ et al. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum 2006;54:3799-808.
67. Schuerwegh AJ, Ioan-Facsinay A, Dorjee AL, Roos J, Bajema IM, van der Voort EI et al. Evidence for a functional role of IgE anticitrullinated protein antibodies in rheumatoid arthritis. Proc Natl Acad Sci USA 2010;107:2586-91.
68. Pamuk GE, Vural O, Turgut B, Demir M, Pamuk ON, Cakir N. Increased platelet activation markers in rheumatoid arthritis: are they related with subclinical atherosclerosis? Platelets 2008;19:146-54.
69. Muszbek L, Adany R, Glukhova MA, Frid MG, Kabakov AE, Koteliansky VE et al. The identification of vimentin in human blood platelets. Eur J Cell Biol 1987;43:501-4.
70. Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol 2012;34:43-62.
71. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903-11.
72. Li P, Li M, Lindberg MR, Kennett MJ, Xiong N, Wang Y et al. PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J Exp Med 2010;207:1853-62.
73. Yamada R, Yamamoto K. Mechanisms of disease: genetics of rheumatoid arthritis-ethnic differences in disease-associated genes. Nat Clin Pract Rheumatol 2007;3:644-50.
74. Raijmakers R, van Beers JJ, El-Azzouny M, Visser NF, Bozic B, Pruijn GJ et al. Elevated levels of fibrinogen-derived endogenous citrullinated peptides in synovial fluid of rheumatoid arthritis patients. Arthritis Res Ther 2012;14:R114.
75. Takizawa Y, Suzuki A, Sawada T, Ohsaka M, Inoue T, Yamada R et al. Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids. Ann Rheum Dis 2006;65:1013-20.
76. Tabushi Y, Nakanishi T, Takeuchi T, Nakajima M, Ueda K, Kotani T et al. Detection of citrullinated proteins in synovial fluids derived from patients with rheumatoid arthritis by proteomics-based analysis. Ann Clin Biochem 2008;45:413-7.
77. Knijff-Dutmer EA, Koerts J, Nieuwland R, Kalsbeek-Batenburg EM, van de Laar MA. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum 2002;46:1498-503.
78. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996;97:2063-73.
79. Duffau P, Seneschal J, Nicco C, Richez C, Lazaro E, Douchet I et al. Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Sci Transl Med 2010;2:47ra63.
80. Ferreira GA, Navarro TP, Telles RW, Andrade LE, Sato EI. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 2007;46:1560-5.
81. Mok CC, Wong CK, To CH, Lai JP, Lam CS. Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken) 2011;63:875-83.
82. Dhar JP, Andersen J, Essenmacher L, Ager J, Bentley G, Sokol RJ et al. Thrombophilic patterns of coagulation factors in lupus. Lupus 2009;18:400-6.
83. Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 2009;68:238-41.
84. Gustafsson JT, Simard JF, Gunnarsson I, Elvin K, Lundberg IE, Hansson LO et al. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther 2012;14:R46.
85. Arnout J, Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost 2003;1:931-42.
86. Pierangeli SS, Vega-Ostertag ME, Gonzalez EB. New targeted therapies for treatment of thrombosis in antiphospholipid syndrome. Expert Rev Mol Med 2007;9:1-15.
87. Lood C, Eriksson S, Gullstrand B, Jonsen A, Sturfelt G, Truedsson L et al. Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus-a possible link to venous thrombosis? Lupus 2012;21:1423-32.
88. Navratil JS, Manzi S, Kao AH, Krishnaswami S, Liu CC, Ruffing MJ et al. Platelet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum 2006;54:670-4.
89. Postlethwaite AE, Chiang TM. Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 2007;19:574-9.
90. Maugeri N, Franchini S, Campana L, Baldini M, Ramirez GA, Sabbadini MG et al. Circulating platelets as a source of the damage-associated molecular pattern HMGB1 in patients with systemic sclerosis. Autoimmunity 2012;45:584-7.
91. Yoshizaki A, Komura K, Iwata Y, Ogawa F, Hara T, Muroi E et al. Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol 2009;29:180-9.
92. Gauley J, Pisetsky DS. The translocation of HMGB1 during cell activation and cell death. Autoimmunity 2009;42:299-301.
93. Rouhiainen A, Imai S, Rauvala H, Parkkinen J. Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation. Thromb Haemost 2000;84:1087-94.
94. Raucci A, Palumbo R, Bianchi ME. HMGB1: a signal of necrosis. Autoimmunity 2007;40:285-9.
95. Dees C, Akhmetshina A, Zerr P, Reich N, Palumbo K, Horn A et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011;208:961-72.
96. Belch JJ, O'Dowd A, Forbes CD, Sturrock RD. Platelet sensitivity to a prostacyclin analogue in systemic sclerosis. Br J Rheumatol 1985;24:346-50.
97. Truchetet ME, Allanore Y, Montanari E, Chizzolini C, Brembilla NC. Prostaglandin I(2) analogues enhance already exuberant Th17 cell responses in systemic sclerosis. Ann Rheum Dis 2012;71:2044-50.
98. Trapp BD, Bo L, Mork S, Chang A. Pathogenesis of tissue injury in MS lesions. J Neuroimmunol 1999;98:49-56.
99. Christensen S, Farkas DK, Pedersen L, Miret M, Christiansen CF, Sorensen HT. Multiple sclerosis and risk of venous thromboembolism: a population-based cohort study. Neuroepidemiology 2012;38:76-83.
100. Sheremata WA, Jy W, Horstman LL, Ahn YS, Alexander JS, Minagar A. et al. Evidence of platelet activation in multiple sclerosis. J Neuroinflammation 2008;5:27.
101. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002;8:500-8.
102. Callea L, Arese M, Orlandini A, Bargnani C, Priori A, Bussolino F. Platelet activating factor is elevated in cerebral spinal fluid and plasma of patients with relapsing-remitting multiple sclerosis. J Neuroimmunol 1999;94:212-21.
103. Kihara Y, Ishii S, Kita Y, Toda A, Shimada A, Shimizu T. Dual phase regulation of experimental allergic encephalomyelitis by platelet-activating factor. J Exp Med 2005;202:853-63.
104. Hofstetter HH, Mossner R, Lesch KP, Linker RA, Toyka KV, Gold R. Absence of reuptake of serotonin influences susceptibility to clinical autoimmune disease and neuroantigen-specific interferon-gamma production in mouse EAE. Clin Exp Immunol 2005;142:39-44.
105. Mostert JP, Admiraal-Behloul F, Hoogduin JM, Luyendijk J, Heersema DJ, van Buchem MA et al. Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. J Neurol Neurosurg Psychiatry 2008;79:1027-31.
106. Thornton P, McColl BW, Greenhalgh A, Denes A, Allan SM, Rothwell NJ et al. Platelet interleukin-1alpha drives cerebrovascular inflammation. Blood 2010;115:3632-9.
107. Davalos D, Ryu JK, Merlini M, Baeten KM, Le Moan N, Petersen MA et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun 2012;3:1227.
108. Schachtrup C, Ryu JK, Helmrick MJ, Vagena E, Galanakis DK, Degen JL et al. Fibrinogen triggers astrocyte scar formation by promoting the availability of active TGF-beta after vascular damage. J Neurosci 2010;30:5843-54.
109. Hussain M, Javeed A, Ashraf M, Zhao Y, Mukhtar MM, Rehman MU. Aspirin and immune system. Int Immunopharmacol 2012;12:10-20.
110. Avalos I, Chung CP, Oeser A, Milne GL, Borntrager H, Morrow JD et al. Aspirin therapy and thromboxane biosynthesis in systemic lupus erythematosus. Lupus 2007;16:981-6.
111. Hohlfeld T, Saxena A, Schror K. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs - pharmacological mechanisms and clinical relevance. Thromb Haemost 2012;109. [Epub ahead of print].
112. Colebatch AN, Marks JL, van der Heijde DM, Edwards CJ. Safety of nonsteroidal antiinflammatory drugs and/or paracetamol in people receiving methotrexate for inflammatory arthritis: a Cochrane systematic review. J Rheumatol Suppl 2012;90:62-73.
113. Amadio S, Montilli C, Magliozzi R, Bernardi G, Reynolds R, Volonte C et al. P2Y12 receptor protein in cortical gray matter lesions in multiple sclerosis. Cereb Cortex 2010;20:1263-73.
114. Garcia AE, Mada SR, Rico MC, Dela Cadena RA, Kunapuli SP. Clopidogrel, a P2Y12 receptor antagonist, potentiates the inflammatory response in a rat model of peptidoglycan polysaccharide-induced arthritis. PLoS One 2011;6:e26035.
115. Su X, Floyd DH, Hughes A, Xiang J, Schneider JG, Uluckan O et al. The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling. J Clin Invest 2012;122:3579-92.
116. de Souza Brito F, Tricoci P. Novel anti-platelet agents: focus on thrombin receptor antagonists. J Cardiovasc Transl Res 2013. [Epub ahead of print].
117. O'Donoghue ML, Bhatt DL, Flather MD, Goto S, Angiolillo DJ, Goodman SG et al. Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program. J Thromb Thrombolysis 2012;34:36-43.
118. Morris R, Winyard PG, Brass LF, Blake DR, Morris CJ. Thrombin receptor expression in rheumatoid and osteoarthritic synovial tissue. Ann Rheum Dis 1996;55:841-3.
119. Yang YH, Hall P, Little CB, Fosang AJ, Milenkovski G, Santos L et al. Reduction of arthritis severity in protease-activated receptor-deficient mice. Arthritis Rheum 2005;52:1325-32.
120. Xue M, Chan YK, Shen K, Dervish S, March L, Sambrook PN et al. Protease-activated receptor 2, rather than protease-activated receptor 1, contributes to the aggressive properties of synovial fibroblasts in rheumatoid arthritis. Arthritis Rheum 2012;64:88-98.
121. Deng X, Mercer PF, Scotton CJ, Gilchrist A, Chambers RC. Thrombin induces fibroblast CCL2/JE production and release via coupling of PAR1 to Galphaq and cooperation between ERK1/2 and Rho kinase signaling pathways. Mol Biol Cell 2008;19:2520-33.
122. Huang CY, Chen SY, Tsai HC, Hsu HC, Tang CH. Thrombin induces epidermal growth factor receptor transactivation and CCL2 expression in human osteoblasts. Arthritis Rheum 2012;64:3344-54.